Share:
What Happened: Medical technology company
Senseonics Holdings (NYSE: SENS) reported results from a PROMISE study evaluating its Eversense CGM System for up to 180 days. The Eversense CGM is a continuous glucose monitoring device.
The overall mean absolute relative difference was 9.1% for the primary sensor and 8.5% for the SBA sensor. The study included over 49,000 paired points for the primary sensor and over 12,000 paired points for the SBA sensor.
The confirmed hypoglycemic alert detection rate was 93% for the primary sensor and 94% for the SBA sensor.
No serious negative events were reported from 181 study participants. A reported 1.1%% of patients had a mild infection at the procedure site.